Left ventricular outflow tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy

Georgios K Efthimiadis1, Despina G Parcharidou, Georgios Giannakoulas

  • 1First Cardiology Department, Cardiomyopathies Laboratory, Aristotle University of Thessaloniki Medical School, AHEPA Hospital, Thessaloniki, Greece. efthymos@med.auth.gr

Insights

Left ventricular outflow tract obstruction (LVOTO) at rest does not appear to be an independent risk factor for sudden death (SD) in hypertrophic cardiomyopathy patients. Other factors like syncope and wall thickness are more significant indicators for SD risk.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Genetics

Background:

  • Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease.
  • Sudden death (SD) is a major concern in HCM patients.
  • The role of left ventricular outflow tract obstruction (LVOTO) at rest in predicting SD in HCM remains controversial.

Purpose of the Study:

  • To evaluate the potential of resting left ventricular outflow tract obstruction (LVOTO) as a novel risk factor for sudden death (SD) in patients with hypertrophic cardiomyopathy (HCM).

Main Methods:

  • A cohort study involving 166 patients with HCM (112 men, mean age 51.8 years).
  • Patients were assessed for peak instantaneous LVOTO gradients at rest (≥30 mm Hg).
  • Follow-up median of 32.4 months for adverse cardiac events including SD, cardiac arrest, VT, or ICD discharge.

Main Results:

  • 13 patients experienced adverse events during follow-up.
  • Cumulative event-free survival was 92% in both LVOTO and non-LVOTO groups (p=NS).
  • Resting LVOTO showed a low positive predictive value (8%) but high negative predictive value (92%) for SD. Syncope and maximal wall thickness ≥3 cm were significant risk factors for SD.

Conclusions:

  • Resting left ventricular outflow tract obstruction (LVOTO) is not supported as an independent risk factor for sudden death (SD) in hypertrophic cardiomyopathy (HCM).
  • Syncope and marked left ventricular hypertrophy (wall thickness ≥3 cm) are more significant predictors of SD in HCM patients.
  • Further research may focus on combined risk stratification models for HCM.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...